

Ficant
5/10/01
pathological response in the mammal when administered
parenterally.

Claim 2, line 1, delete "a systemic" and insert
therefor --an--;

line 2, after "the mammal", insert --having
such a condition--.

REMARKS

Claims 1-5, 7-13, and 15-24 presently appear in this case. No claims have been allowed. On March 21, 2000, applicants filed an amendment responsive to the official action of October 21, 1999. The present supplemental amendment is intended to supplement applicants' amendment of March 21, 2000, and to present additional reasons why the present claims are unobvious from the prior art of record.

In applicants' amendment of March 21, 2000, applicants argued over the Samo and Iida references on the ground that the nasal spray was intended to administer the interferon into the lungs, rather than the oromucosal cavity. These arguments are well supported with respect to Iida because Iida has specific language stating that the administration site is the lung. However, Samo merely refers to the use of a "metered dose spray bottle", although it also refers to the method of administration which has been previously described in footnote 1, i.e., Samo et al,